JAMA Intern Med.Published online June 1, 2020. doi:10.1001/jamainternmed.2020.1308
Concern about high out-of-pocket spending for insulin has prompted states, payers, and pharmacy benefit managers to limit cost-sharing in the US.1,2In addition to insulin, patients with type 1 diabetes might have out-of-pocket expenses for other care, such as diabetes-related supplies. Using national 2018 claims data, we estimated out-of-pocket spending for insulin and other health care services for privately insured patients with type 1 diabetes.
Comments